David M. Nanus

Active 1987–2025

116
Papers
25,907
Citations
77
h-index
115
i10-index

Citations

Citations per year for David M. Nanus1991: 2 citations1992: 2 citations1993: 16 citations1994: 16 citations1995: 22 citations1996: 21 citations1997: 32 citations1998: 40 citations1999: 60 citations2000: 63 citations2001: 50 citations2002: 62 citations2003: 57 citations2004: 92 citations2005: 83 citations2006: 81 citations2007: 82 citations2008: 83 citations2009: 86 citations2010: 89 citations2011: 113 citations2012: 122 citations2013: 153 citations2014: 198 citations2015: 185 citations2016: 289 citations2017: 336 citations2018: 403 citations2019: 967 citations2020: 1,107 citations2021: 1,215 citations2022: 872 citations2023: 590 citations2024: 1,035 citations2025: 413 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,377 citing papers, 31% of this breakdownChina: 888 citing papers, 8.2% of this breakdownUnited Kingdom: 681 citing papers, 6.2% of this breakdownGermany: 589 citing papers, 5.4% of this breakdownCanada: 574 citing papers, 5.3% of this breakdownItaly: 552 citing papers, 5.1% of this breakdownFrance: 384 citing papers, 3.5% of this breakdownAustralia: 347 citing papers, 3.2% of this breakdownJapan: 318 citing papers, 2.9% of this breakdownSpain: 305 citing papers, 2.8% of this breakdownNetherlands: 291 citing papers, 2.7% of this breakdownSwitzerland: 274 citing papers, 2.5% of this breakdown
0%31%Other 21.2%

Fields

  • Medicine69.9%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.3%
  • Engineering1.7%
  • Neuroscience0.8%
  • Materials Science0.5%
  • Other1.3%

Topics

  • Prostate Cancer Treatment and Research14.9%
  • Prostate Cancer Diagnosis and Treatment5.9%
  • Radiopharmaceutical Chemistry and Applications4.8%
  • Cancer Genomics and Diagnostics4.1%
  • Cancer Cells and Metastasis2.5%
  • Renal cell carcinoma treatment2.4%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  2. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 cited by 1,729

  3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  4. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2011 cited by 1,020

  5. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 cited by 209

  6. Patient derived organoids to model rare prostate cancer phenotypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesca Demichelis, Mark A. Rubin, Himisha Beltran - Nature Communications 2018 cited by 356

  7. Clinical features of neuroendocrine prostate cancer

    Authors: , , , , , , , , , , , , , - European Journal of Cancer 2019 cited by 363

  8. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 364

  9. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 275

  10. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  11. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2020 cited by 192

  12. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 129

  13. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 88

  14. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 67

  15. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , - Clinical Cancer Research 2013 cited by 426

  16. Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

    Authors: , , , , , , , , , , , , - Neoplasia 2013 cited by 249

  17. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 212

  18. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

    Authors: , , , , , - Journal of Clinical Oncology 2005 cited by 508

  19. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 374

  20. Clonal evolution of chemotherapy-resistant urothelial carcinoma

    Authors: , , , , , , , , , , , , , - Nature Genetics 2016 cited by 301

  21. Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

    Authors: , , , , , , , , , , , , , - European Urology 2012 cited by 457

  22. Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer

    Authors: , , , , , , , , , , , - Cancer 2019 cited by 133

  23. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

    Authors: , , , , , , , , , , , , , , , - Molecular Cancer Therapeutics 2020 cited by 71

  24. Renal-Cell Carcinoma

    Authors: , , - New England Journal of Medicine 1996 cited by 2,248